MRKR · Company research
Marker Therapeutics, Inc. (MRKR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer | Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support Phase 1 clinical studies of MT-601, its multi-antigen recognizing T cell therapy, in locally advanced unresectable pancreatic cancer. The award represents competitive recognition of the company's MAR-T platform, which has shown a disease control rate of 84.6% in earlier studies. Clinical initiation is anticipated in Q1 2027. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| APP,RCAT,CCC,OPTU,INOD,MRKR,RNAC,OKLO,ARDX,AJG | Stock Prices | Quote Comparison - Yahoo! Finance Canada | APP,RCAT,CCC,OPTU,INOD,MRKR,RNAC,OKLO,ARDX,AJG | Stock Prices | Quote Comparison Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy | Marker Therapeutics (MRKR) has been upgraded to a Zacks Rank #1 (Strong Buy) rating due to rising earnings estimates. The company's consensus estimate has increased 45.3% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects an improving business outlook that could drive near-term stock price appreciation. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| New Strong Buy Stocks for October 16th | Zacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| New Strong Buy Stocks for October 16th | Zacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Marker Therapeutics Inc. Stock Grades | MRKR - Barron's | Marker Therapeutics Inc. Stock Grades | MRKR Barron's | View source ↗ | Barron's | Oct 10, 2026 | neutral | 0 | 0.6 |
| A new cell-therapy network spans 140,000 square feet for Marker Therapeutics - Stock Titan | A new cell-therapy network spans 140,000 square feet for Marker Therapeutics Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| Marker Therapeutics (MRKR) Holds at $1.24 as Shares Trade Flat Within Range - Collar Trade - dars.gov.et | Marker Therapeutics (MRKR) Holds at $1.24 as Shares Trade Flat Within Range - Collar Trade dars.gov.et | View source ↗ | dars.gov.et | Sep 4, 2026 | neutral | 0 | 0.6 |
| Marker Therapeutics (MRKR) Holds at $1.24 as Shares Trade Flat Within Range - Bull Pennant - https://www.siam.in/ | Marker Therapeutics (MRKR) Holds at $1.24 as Shares Trade Flat Within Range - Bull Pennant https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Sep 4, 2026 | neutral | 0 | 0.6 |
| Marker Therapeutics Inc. (MRKR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research | Marker Therapeutics Inc. (MRKR) Shareholding Pattern – Promoters, FIIs & DIIs Value Research | View source ↗ | Value Research | Sep 1, 2026 | neutral | 0 | 0.6 |
| Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans? - Simply Wall Street | Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans? Simply Wall Street | View source ↗ | Simply Wall Street | Aug 24, 2026 | neutral | 0 | 0.6 |
| H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com | H.C. Wainwright reiterates Marker Therapeutics stock rating at buy Investing.com | View source ↗ | Investing.com | Aug 21, 2026 | neutral | 0 | 0.6 |
| Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook - Simply Wall Street | Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook Simply Wall Street | View source ↗ | Simply Wall Street | Jul 2, 2026 | neutral | 0 | 0.6 |
| MRKR Forecast — Price Target — Prediction for 2027 - TradingView | MRKR Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance | MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Mar 18, 2026 | neutral | 0 | 0.6 |
| MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Yahoo Finance | MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Jan 21, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 29, 2024 | neutral | 0 | 0.6 |
| MARKER THERAPEUTICS (MRKR) - Zacks Investment Research | MARKER THERAPEUTICS (MRKR) Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 19, 2018 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.